Phase 2b trial of a novel extended ‐release microsphere formulation of triamcinolone acetonide for intra‐articular injection in knee osteoarthritis

ConclusionAlthough the primary endpoint was not met, FX006 demonstrated a prolonged reduction in symptoms with an evident dose response and a safety profile similar to that of saline‐placebo.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - October 31, 2017 Category: Rheumatology Authors: Philip G Conaghan, Stanley B Cohen, Francis Berenbaum, Joelle Lufkin, James R Johnson, Neil Bodick Tags: Brief Report Source Type: research